| 10/22 | ROCHE : FDA Approves Genentech's Susvimo, a First-of-Its-Kind Therapeutic Approach for Wet.. | BU |
| 10/22 | ROCHE : FDA approves Roche's Susvimo, a first-of-its-kind therapeutic approach for neovasc.. | AQ |
| 10/22 | Lymphoma Hub maintains its focus on raising the levels of global knowledge of lymphoma .. | AQ |
| 10/22 | ROCHE : VENTANA PD-L1 (SP263) Assay receives FDA approval as a companion diagnostic to ide.. | AQ |
| 10/21 | CHUGAI PHARMACEUTICAL : Contribution of Para-transit Vehicles to Welfare Services | AQ |
| 10/21 | ROCHE : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Third Quarter Sal.. | AQ |
| 10/20 | ROCHE : Nine-month 2021 Investor update | PU |
| 10/20 | ROCHE : reports strong growth in the first nine months – outlook for 2021 raised - I.. | PU |
| 10/20 | ROCHE : Nine-month 2021 Presentation without appendix | PU |
| 10/20 | ROCHE : Nine-month 2021 Presentation with appendix | PU |
| 10/20 | ROCHE : reports strong growth in the first nine months – outlook for 2021 raised | AQ |
| 10/15 | ROCHE : FDA Approves Genentech's Tecentriq as Adjuvant Treatment for Certain People With E.. | BU |
| 10/15 | ROCHE : US FDA approves Roche's Tecentriq as adjuvant treatment for certain people with ea.. | AQ |
| 10/15 | ROCHE : announces PathAI collaboration for artificial intelligence-based digital pathology.. | AQ |
| 10/14 | ROCHE : FDA accepts REGEN-COV (casirivimab and imdevimab) for priority review for treatmen.. | PU |
| 10/14 | ROCHE : Invitation to Roche's Virtual Event "Digitalization along the value chain" | PU |
| 10/14 | ROCHE : New four-year data show Roche's ENSPRYNG significantly reduces debilitating relaps.. | AQ |
| 10/14 | ROCHE : New 4-Year Data Show Genentech's Enspryng (satralizumab-mwge) Significantly Reduce.. | BU |
| 10/14 | ROCHE : Gazyvaro shorter 90-minute infusion time approved in Europe for people with previo.. | AQ |
| 10/13 | REMINDER : Invitation to Roche's 3rd Quarter Sales 2021 Webinar | PU |
| 10/13 | ROCHE : New Data up to 8-Years for Genentech's Ocrevus (ocrelizumab) Show Early and Ongoin.. | BU |
| 10/13 | ROCHE : Data up to 8-years for Roche's OCREVUS (ocrelizumab) show early and ongoing treatm.. | AQ |
| 10/12 | CombiGene and Spark Therapeutics enter exclusive, global licensing agreement for gene t.. | AQ |
| 10/11 | ROCHE : Chugai files for additional indications of Ronapreve for prophylaxis and treatment.. | PU |
| 10/08 | ROCHE : anti-amyloid beta antibody gantenerumab granted FDA Breakthrough Therapy Designati.. | AQ |
| 10/08 | GENENTECH : 's Anti-Amyloid Beta Antibody Gantenerumab Granted FDA Breakthrough Therapy De.. | BU |
| 10/05 | GENENTECH : to Present New Data on Ocrevus (ocrelizumab) in Multiple Sclerosis and Enspryn.. | BU |
| 10/05 | ROCHE : to present new data on OCREVUS in multiple sclerosis and ENSPRYNG in neuromyelitis.. | AQ |
| 10/04 | CHUGAI PHARMACEUTICAL : Receives Orphan Drug Designation for Hemlibra in Acquired Hemophil.. | AQ |
| 10/04 | CHOROIDEREMIA PIPELINE : Industry Analysis, Drugs, Pipeline, Treatment and Key Companies b.. | AQ |
| 10/01 | ROCHE : Phase II/III trial shows Ronapreve (casirivimab and imdevimab) significantly reduc.. | AQ |
| 09/30 | ROCHE : Phase II/III trial shows Ronapreve™ (casirivimab and imdevimab) significantl.. | AQ |
| 09/28 | CHUGAI PHARMACEUTICAL : Zenyaku Kogyo Co. and Chugai Pharmaceutical Co. - Anti-CD20 Monocl.. | AQ |
| 09/24 | ROCHE : presents new data at World Muscle Society (WMS) 2021 highlighting new advances for.. | AQ |
| 09/23 | ROCHE : Canadian Blood Services selects Roche Diagnostics Canada as a partner of choice fo.. | AQ |
| 09/22 | ROCHE : launches three respiratory test panels on cobas 6800/8800 Systems in CE markets to.. | AQ |
| 09/21 | ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-Stage Lun.. | AQ |
| 09/20 | ROCHE : Booster programme welcome but plans must be in place for boosters for all vaccinat.. | AQ |
| 09/20 | ROCHE : New Phase III Data Support the Benefit of Genentech's Tecentriq in Early-stage Lun.. | BU |
| 09/20 | ROCHE : New Phase III data support the benefit of Roche's Tecentriq in early-stage lung ca.. | AQ |
| 09/20 | ROCHE : Invitation to Roche's 3rd Quarter Sales 2021 Webinar | PU |
| 09/17 | ROCHE : receives positive CHMP opinion for Gavreto® (pralsetinib) for the treatment of adu.. | AQ |
| 09/17 | ROCHE : presents first phase II data on giredestrant, a next generation selective oestroge.. | PU |
| 09/15 | ROCHE : opens access to pathology imaging tools to improve patient care | AQ |
| 09/09 | ROCHE : signs definitive share purchase agreement with long-term partner TIB Molbiol to ex.. | AQ |
| 09/07 | REMINDER : Invitation to Roche's Virtual Pharma Day - Tuesday, 14th September 2021 | PU |
| 09/07 | ROCHE : Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Deve.. | AQ |
| 09/07 | ROCHE : to present data from industry leading portfolio at ESMO 2021 showing significant p.. | AQ |
| 09/07 | GENENTECH : to Present Data From Industry-Leading Portfolio at ESMO 2021 Showing Significa.. | BU |
| 08/30 | ROCHE : Partners with the Kolisi Foundation, One By One Target Covid Campaign and Transnet.. | BU |
| 08/30 | ROCHE : Genentech Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metasta.. | AQ |
| 08/27 | GENENTECH : Provides Update on Tecentriq U.S. Indication for PD-L1-Positive, Metastatic Tr.. | BU |
| 08/27 | ROCHE : provides update on Tecentriq US indication for PD-L1-positive, metastatic triple-n.. | AQ |
| 08/26 | ROCHE : Shlomo Zalman (Sam) Bregman, a Fox News Commentator, Prominent Rabbi, and Manager .. | AQ |
| 08/24 | ROCHE : Shape Therapeutics enters into a strategic research collaboration with Roche to ad.. | AQ |
| 08/23 | ROCHE : First monoclonal antibody treatment for COVID-19 approved for use in the UK | AQ |
| 08/19 | ROCHE : Joint Statement From Unitaid and the World Health Organization (On Behalf of the A.. | AQ |
| 08/18 | JOHNSON & JOHNSON : WHO urges J&J to stop shipping Covid vaccines from Africa to rich coun.. | AQ |
| 08/18 | ROCHE : receives FDA approval for first companion diagnostic to identify dMMR solid tumour.. | AQ |
| 08/09 | ROCHE : Phase III study shows Roche's Polivy plus R-CHP is the first regimen in 20 years t.. | AQ |
| 08/09 | ROCHE : Phase III Study Shows Genentech's Polivy Plus R-CHP Is the First Regimen in 20 Yea.. | BU |
| 08/04 | ROCHE : FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Cert.. | AQ |
| 08/03 | ROCHE : US FDA grants Priority Review to Roche's Tecentriq as adjuvant treatment for certa.. | AQ |
| 08/03 | ROCHE : FDA Grants Priority Review to Genentech's Tecentriq as Adjuvant Treatment for Cert.. | BU |
| 08/02 | ROCHE : FDA expands authorized use of REGEN-COV (casirivimab and imdevimab) | PU |
| 07/30 | ROCHE : Invitation to Roche's Virtual Pharma Day - Tuesday, 14th September 2021 | PU |
| 07/29 | PTC THERAPEUTICS : Significant Improvements in Survival and Developmental Milestones Demon.. | AQ |
| 07/29 | ROCHE : FDA accepts application for Roche's faricimab for the treatment of neovascular age.. | AQ |
| 07/29 | ROCHE : FDA Accepts Application for Genentech's Faricimab for the Treatment of Wet Age-Rel.. | BU |
| 07/29 | ROCHE : Data for Roche's Evrysdi® (risdiplam) published in New England Journal of Medicine.. | AQ |
| 07/28 | ROCHE : Data for Genentech's Evrysdi (risdiplam) Published in New England Journal of Medic.. | BU |
| 07/26 | ROCHE : Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Half Year Results.. | AQ |
| 07/22 | ROCHE : Half-year 2021 Investor Update | PU |
| 07/22 | ROCHE : Half Year Report 2021 | PU |
| 07/22 | ROCHE : reports good half-year results - Investor Update | PU |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
